IE 11 is a very old Browser and it`s not supported on this site
Financial Report Financial statements

Balance sheet as at December 31 

in CHF

Notes

2023

2022

Current assets

Cash and cash equivalents

44 757

116 430

Other current receivables

5 992 571

5 558 139

6 037 328

5 674 569

Non-current assets

Investments

1 177 069 500

1 177 069 500

1 177 069 500

1 177 069 500

Total assets

1 183 106 828

1 182 744 069

Current liabilities

Other current liabilities

2.1

334 219

325 013

Accrued expenses

467 774

509 994

801 993

835 007

Total liabilities

801 993

835 007

Shareholders' equity

Share capital

2.2

11 080 000

11 080 000

Legal capital reserves

- Paid-in capital reserve 1)

20 579 224

20 579 224

Legal profit reserves

- General legal reserve

4 500 000

4 500 000

- Reserve for treasury shares 2)

36 508 182

36 508 182

Other reserves

190 319 574

190 319 574

Retained earnings

5/6

919 317 855

918 922 082

1 182 304 835

1 181 909 062

Total liabilities and shareholders' equity

1 183 106 828

1 182 744 069

1Of which CHF 20 441 000 not confirmed by the Swiss Tax Authorities due to present regulation

2For treasury shares held by subsidiaries

The financial statements were approved by the Board of Directors of BB Biotech AG on February 13, 2024.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer